PATENT CLAIM ANALYSIS

Application Number: 16227307
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "130100"]

Abstract:
Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.

Claim (Index 1):
A method of antagonizing signal transduction in dorsal root ganglion cells in a subject, comprising subcutaneously administering to the subject a humanized monoclonal antibody that specifically binds to a first receptor consisting of amino acid residues 1-662 of SEQ ID NO:8, or a second receptor consisting of amino acid residues 1-979 of SEQ ID NO:16, or a heterodimeric receptor comprising the first and second receptors, wherein the isotype of the antibody is IgG2, and wherein after administration of the antibody, signal transduction through the heterodimeric receptor induced by a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2 is reduced.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.43182
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13788454', '12395095', '12607831', '15461090', '13332758']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7079710446975392
- 35 USC 102 Novelty (BERT): 0.5615793329185651
- Combined Prediction Score: 0.6933318735196418
- Mean Citation Score: 325.4615520000001
- Max Citation Score: 417.9725
- Similarity Product: 405.3340333321691

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test